Uncategorized

Protaryx Medical, an innovative medical device company developing disruptive access solutions for minimally invasive left-heart procedures, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its proprietary Transseptal Puncture Device. This submission marks a major milestone in the Company’s mission to redefine safe, efficient and…

[Baltimore Maryland, September 11, 2023] – Protaryx Medical, a pioneering leader in medical device innovation, proudly announces the appointment of David Mester, MBA as its new Chief Executive Officer (CEO). With a remarkable career spanning over 30 years in the structural heart medical device industry, David Mester brings a wealth of experience and expertise to…